| Code | CSB-MP326981HUd7 |
| Abbreviation | Recombinant Human AXL protein, partial (Active) |
| MSDS | |
| Size | $9.9 |
| Promotion | |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
AXL receptor tyrosine kinase drives tumor progression, immune evasion, and therapeutic resistance across multiple cancer types, making it a high-priority target for antibody and small-molecule drug discovery. This recombinant human AXL construct spans the extracellular domain (aa 26–451), covering both immunoglobulin-like and fibronectin type III repeats critical for ligand engagement and antibody recognition. Functional ELISA confirms robust binding activity, with an EC50 of 1.308–1.500 ng/mL against an anti-AXL recombinant antibody, supporting use in ligand-receptor interaction assays, competitive blocking antibody screening, therapeutic antibody epitope mapping, and affinity characterization by SPR or BLI. Mammalian cell expression preserves native glycosylation and conformational integrity essential for these binding studies, while purity exceeding 95% and endotoxin levels below 1.0 EU/μg satisfy the criteria typical for cell-based functional assays and sensitive biophysical measurements.
There are currently no reviews for this product.